As I look over the current inventory of illnesses
Post# of 148292
(Total Views: 629)
Posted On: 09/12/2022 2:08:50 PM
As I look over the current inventory of illnesses CYDY is involved with, I note that each indication has a fairly long tail, very costly trials and a highly competitive field of ruthless BP adversaries.
The strategy that has been deployed seems to lack a concern for costs and ROI considerations, not to mention the competitive environment and our friends over at the FDA.
As you look over ohm's list of 90 indications, surely a few less dramatic conditions could be well served at a fraction of the cost involved in running a trial. I am not a doctor, but I suspect there are no shortage of sepsis patients that would benefit from a fairly short-term trial with LL. Humor me, alopecia areata, baldness would be another low-profile disorder that would generate ample revenue upon approval. I'm sure you can find a few more on the list that would fit the bill.
If CYDY is going to move forward, logic would seem to indicate a well thought out plan of action that will get across the finish line in an efficient manner. We seem to have taken on the big five human ailments and expected to get it done on the cheap and in short order.
Why are we surprised that the big dogs come out after us when we try to play in their back yard. If we can just pinch out a couple approvals for some of the less romantic illnesses, we could be on the way to bigger approvals.
The strategy that has been deployed seems to lack a concern for costs and ROI considerations, not to mention the competitive environment and our friends over at the FDA.
As you look over ohm's list of 90 indications, surely a few less dramatic conditions could be well served at a fraction of the cost involved in running a trial. I am not a doctor, but I suspect there are no shortage of sepsis patients that would benefit from a fairly short-term trial with LL. Humor me, alopecia areata, baldness would be another low-profile disorder that would generate ample revenue upon approval. I'm sure you can find a few more on the list that would fit the bill.
If CYDY is going to move forward, logic would seem to indicate a well thought out plan of action that will get across the finish line in an efficient manner. We seem to have taken on the big five human ailments and expected to get it done on the cheap and in short order.
Why are we surprised that the big dogs come out after us when we try to play in their back yard. If we can just pinch out a couple approvals for some of the less romantic illnesses, we could be on the way to bigger approvals.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼